Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 16/20 | 0.46 |
| ▸ | CNR1 | P21554 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19932656 | 1.00 | CHRM1 (0.46) | CHRM1CNR1 | |
| SCHEMBL19932665 | 0.91 | CHRM1 (0.47) | CHRM1 | |
| SCHEMBL19932666 | 0.88 | CHRM1 (0.54) | CHRM1 | |
| SCHEMBL19932705 | 0.85 | CHRM1 (0.51) | CHRM1 | |
| SCHEMBL19932668 | 0.84 | CHRM1 (0.53) | CHRM1 | |
| SCHEMBL19932663 | 0.84 | CHRM1 (0.53) | CHRM1 | |
| SCHEMBL21545733 | 0.84 | CHRM1 (0.53) | CHRM1 | |
| SCHEMBL19932667 | 0.84 | CHRM1 (0.52) | CHRM1 | |
| SCHEMBL19932711 | 0.84 | CHRM1 (0.49) | CHRM1CNR1 | |
| SCHEMBL21545713 | 0.80 | CHRM1 (0.69) | CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11040026-B2 | Muscarinic M1 receptor positive allosteric modulators | SUVEN LIFE SCIENCES LIMITED (IN) | 2021-06-22 | — | — | US | claimed |
| EP-3507289-B1 | MUSCARINIC M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | SUVEN LIFE SCIENCES LTD (IN) | 2020-07-15 | — | — | EP | claimed |
| US-20190343812-A1 | MUSCARINIC M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | SUVEN LIFE SCIENCES LIMITED (IN) | 2019-11-14 | — | — | US | claimed |
| US-11040026-B2 | Muscarinic M1 receptor positive allosteric modulators | SUVEN LIFE SCIENCES LIMITED (IN) | 2021-06-22 | — | — | US | disclosed |
| EP-3507289-B1 | MUSCARINIC M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | SUVEN LIFE SCIENCES LTD (IN) | 2020-07-15 | — | — | EP | disclosed |
| US-20190343812-A1 | MUSCARINIC M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | SUVEN LIFE SCIENCES LIMITED (IN) | 2019-11-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11040026-B2 | Muscarinic M1 receptor positive allosteric modulators | CHRM1, CHRM2, CHRM3 | CHRM1 1/4885CNR1 89/4885 |
| US-20190343812-A1 | MUSCARINIC M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | CHRM1, CHRM2, CHRM3 | CHRM1 1/4885CNR1 89/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.